Peptide-drug conjugates: a new hope for cancer management

[thumbnail of molecules-27-07232-v3.pdf]
molecules-27-07232-v3.pdf - Published Version (1MB) | Preview
Available under license: Creative Commons Attribution

Chavda, Vivek P ORCID: 0000-0002-7701-8597, Solanki, Hetvi K, Davidson, Majid ORCID: 0000-0002-3241-6444, Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771 and Bojarska, Joanna ORCID: 0000-0001-9190-6913 (2022) Peptide-drug conjugates: a new hope for cancer management. Molecules, 27 (21). ISSN 1420-3049


Cancer remains the leading cause of death worldwide despite advances in treatment options for patients. As such, safe and effective therapeutics are required. Short peptides provide advantages to be used in cancer management due to their unique properties, amazing versatility, and progress in biotechnology to overcome peptide limitations. Several appealing peptide-based therapeutic strategies have been developed. Here, we provide an overview of peptide conjugates, the better equivalents of antibody-drug conjugates, as the next generation of drugs for required precise targeting, enhanced cellular permeability, improved drug selectivity, and reduced toxicity for the efficient treatment of cancers. We discuss the basic components of drug conjugates and their release action, including the release of cytotoxins from the linker. We also present peptide-drug conjugates under different stages of clinical development as well as regulatory and other challenges.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.3390/molecules27217232
Official URL
Subjects Current > FOR (2020) Classification > 3202 Clinical sciences
Current > Division/Research > Institute for Health and Sport
Keywords cancer management, cancer treatment, peptide drug conjugates, clinical development
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login